My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Aptose Biosciences Inc. ("Aptose” or the "Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...